---
title: "Bicycle Therapeutics presents initial Duravelo-2 data showing comparable ORR and lower toxicity in mUC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287274269.md"
description: "Bicycle Therapeutics reported initial Duravelo-2 data for zelenectide in metastatic urothelial cancer, showing a 65% unconfirmed overall response rate (ORR) and a favorable safety profile. Key findings include a median treatment duration of 6.3 months, with 65% of patients still on treatment. Cohort 2 showed a 37% ORR. Updated Duravelo-1 data indicated a 59% unconfirmed ORR and median progression-free survival of 13.0 months."
datetime: "2026-05-21T21:13:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287274269.md)
  - [en](https://longbridge.com/en/news/287274269.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287274269.md)
---

# Bicycle Therapeutics presents initial Duravelo-2 data showing comparable ORR and lower toxicity in mUC

**Bicycle Therapeutics announced initial Duravelo-2 data showing comparable response rates and a potentially differentiated safety profile for zelenectide in metastatic urothelial cancer.**

**Key Highlights:**

-   Duravelo-2 interim (Week 27) at optimal 6mg dose: 65% ORR unconfirmed, 58% BICR-confirmed ORR (later 62% with an additional confirmed response).
-   At optimal dose median treatment duration 6.3 months; 65% of patients remain on treatment; relative dose intensity 97%.
-   Low rates of zelenectide-related AEs of interest: peripheral neuropathy 33%, skin reactions 17%, eye disorders 10%; no severe skin reactions.
-   Cohort 2 monotherapy (prior-line mUC) showed 37% ORR (30% confirmed), mDOT 4.8 months, relative dose intensity 86%, no treatment discontinuations at optimal dose.
-   Updated Duravelo-1 (cisplatin-ineligible) combo data: 59% ORR unconfirmed, 50% confirmed ORR and median PFS 13.0 months; monotherapy EV‑naïve cohort 38% ORR and median PFS 5.4 months.

Original SEC Filing: BICYCLE THERAPEUTICS PLC \[ BCYC \] - 8-K - May. 21, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BCYC.US](https://longbridge.com/en/quote/BCYC.US.md)

## Related News & Research

- [Will TRUST-II Quality-of-Life Data and Global Milestones Change Nuvation Bio's (NUVB) Narrative?](https://longbridge.com/en/news/288937721.md)
- [10:02 ETQueen City Dermatology Becomes First Cincinnati Practice to Offer XERF Radiofrequency Skin Tightening](https://longbridge.com/en/news/288735262.md)
- [Big Digital Energy Ends 2024 AI/HPC Colocation Agreement With BE Global Development](https://longbridge.com/en/news/289236242.md)
- [Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints](https://longbridge.com/en/news/288488254.md)
- [Better Buy: Sandisk or Nvidia Stock?](https://longbridge.com/en/news/288986978.md)